ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025
Blood biomarkers differentiate AD-related versus non-AD-related cognitive deficits.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- From Cerebrospinal Fluid to Blood Draw: Plasma p-Tau217 as a Non-Invasive Biomarker for Alzheimer's Disease: A Fagan Nomogram-Based Meta-Analytic Study.Molecular neurobiology · 2026Pooled it
- Association between amyloid-β deposition and cognitive function in cognitively normal adults: a multilevel meta-analysis.Alzheimer's research & therapy · 2026Pooled it
- Neurobiological markers across joint profiles of subjective cognitive decline and objective cognitive function in older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Trial
- Cognitive and Brain Reserve as Modifiers of Early Alzheimer Disease-Related Cognitive Vulnerability.Neurology · 2026Trial
- Arterial stiffness moderates the link between NfL and cognition: The IGNITE study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Trial
- Blood Biomarkers of Alzheimer Disease and Rates of Global and Domain-Specific Cognitive Decline.JAMA network open · 2026Article
- Classification accuracies of plasma ptau217 vs. ptau217/Aβ1-42 for brain Aβ pathology in cognitively normal older adults.GeroScience · 2026Observational
- Alzheimer's disease and cerebrovascular biomarkers in relation to odor identification in a naturalistic clinical cohort.Alzheimer's research & therapy · 2026Article
- Physical activity, aerobic fitness, and AD blood biomarkers: The IGNITE study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- The MINT Sprint 2.0: a Picture Naming Test for Detection of Naming Impairments in ΜCI Due or Not to AD, Greek Version.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2026Article
- Dynamical Regulation of Blood Pressure and Cognitive Function.American journal of hypertension · 2026Article
- Streamlined resource-efficient plasma amyloid-beta mass spectrometry assay has improved biomarker performance in preclinical Alzheimer's disease.Nature communications · 2026Article
- The clinical translation of plasma p-tau217 warrants higher urgency than additional efficacy validation studies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Blood biomarkers differentiate AD-related versus non-AD-related cognitive deficits.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Correlation between blood biomarkers and post-stroke cognitive impairment.Frontiers in aging neuroscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
introductionThe utility of blood-based biomarkers for discriminating Alzheimer's disease (AD)-related versus non-AD-related cognitive deficits in preclinical populations remains poorly understood. Here, we tested the capability of blood markers to detect and discriminate variation in performance across multiple cognitive domains in a cognitively unimpaired sample.
methodsParticipants (n = 648, aged 69.9 ± 3.8, 71% female) underwent a comprehensive cognitive assessment and assays for plasma-based biomarkers amyloid beta (Aβ)1-42/1-40 by mass spectrometry, phosphorylated tau (p-tau) 181 and 217, p-tau217/Aβ1-42, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL).
resultsGreater p-tau217 was exclusively associated with poorer episodic memory performance (β = -0.11, SE = 0.04, p = .003), and remained so after covarying for NfL. Higher NfL was non-specifically associated with poorer performance across a range of cognitive domains and remained so after covarying for p-tau217. DISCUSSION: Blood-based biomarkers may differentiate non-AD-related versus AD-related cognitive deficits. This characterization will be important for early intervention and disease monitoring for AD. HIGHLIGHTS: There is heterogeneity in the causes of cognitive decline in aging. AD-related blood biomarkers may help characterize these causes. Elevated p-tau217 was exclusively associated with poorer episodic memory. Elevated NfL was associated with poorer cognition in a broad range of domains. Blood biomarkers may help differentiate AD- and non-AD-related cognitive deficits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.